Ocular Therapeutix (NSDQ:OCUL) shares slid this morning on fourth-quarter results that missed the consensus forecast.
The Bedford, Mass.-based eye disease therapeutic developer posted losses of -$85.6 million, or -$1.21 per share, on sales of $7.3 million for the three months ended Dec. 31, 2020, for a massive bottom-line slide from losses of -$26 million last year despite more than tripling revenue numbers from $2.3 million.
Get the full story at our sister site, Drug Delivery Business News.